Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-Derived Lymphocytes
We will collect immune cells or lymphocytes from the donor's blood using a cell separator.
The blood lymphocytes will be given to the subjects through a catheter. If the subjects
have no complications of the first course of infusions, we may decide to give them
"lymphocytes" aa second time while subjects are in remission in an attempt to prevent their
disease from relapsing. A bone marrow test will be taken prior to infusion of lymphocytes
as part of the clinical evaluation to receive this treatment. After lymphocyte infusions, a
bone marrow will be examined about every three months for the first year to monitor progress
from this therapy.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Freedom of Disease: Bone marrow histology, cytogenetic analysis and RFLP will be studied. Data will be collected and tabulated.
before, at 3 months, 6 months, 9 months and 12 months after donor lymphocyte infusions
Jeffrey Miller, MD
University of Minnesota Medical Center
United States: Institutional Review Board
|University of Minnesota Medical Center||Minneapolis, Minnesota 55455|